Bayhill Therapeutics, Inc. Research On Multiple Sclerosis Chosen As One Of The Meeting’s Scientific Program Highlights At The 58th Annual Meeting Of The American Academy Of Neurology

SAN DIEGO--(BUSINESS WIRE)--April 4, 2006--Bayhill Therapeutics will make two presentations today at the 58th Annual Meeting of the American Academy of Neurology in San Diego in connection with development of the company’s lead drug candidate, BHT-3009, for the treatment of multiple sclerosis.